Levosimendan

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

左西孟旦是一种钙增敏剂，通过钙依赖性结合心肌肌钙蛋白 C (cTnC) 发挥作用，可治疗心力衰竭。

Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC), provides treatment for heart failure.(In Vitro):Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan (OR1259) is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan (OR1259) has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy. The cardiovascular effects of Levosimendan (OR1259) are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators. Levosimendan (OR1259) might reduce mortality in cardiac surgery and cardiology settings of adult patients.

Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan (OR1259) is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan (OR1259) has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy. The cardiovascular effects of Levosimendan (OR1259) are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators. Levosimendan (OR1259) might reduce mortality in cardiac surgery and cardiology settings of adult patients.

——

OR 1259 | Simdax | (R)-Simendan

Membrane Transporter/Ion Channel

Carbonic Anhydrase

Cardiac troponin C

Cardiovascular Disease

——

141505-33-1

280.28

C14H12N6O

>98% (HPLC)

DMSO: 56 mg/mL (199.8 mM)

CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N

2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile

(-20℃)

With Ice Pack

≥ 2 years